利拉鲁肽对肥胖2型糖尿病患者血清人成纤维细胞生长因子21及蛋白酪氨酸磷酸酶1B水平影响的研究

Effect of Liraglutide on serum FGF21 and PTP1B levels in obese patients with type 2 diabetes mellitus

目的观察利拉鲁肽对肥胖T2DM患者血清人成纤维细胞生长因子21(FGF21)及蛋白酪氨酸磷酸酶1B(PTP1B)水平的影响.方法选取2018年3~12月于我院内分泌科住院的口服二甲双胍或磺脲类药物血糖控制不佳的肥胖T2DM患者80例,其中,40例在原口服降糖药治疗基础上加用利拉鲁肽治疗(LI组),另外40例采用二甲双胍+磺脲类药物治疗(Con组),疗程均为16周.分析两组代谢指标及血清FGF21、PTP1B水平变化.结果治疗16周后,两组胰岛素抵抗指数(HOMA-IR)(C-P)、血清FGF21及PTP1B均较治疗前下降(P<0.05),LI组较Con组下降(P<0.05).结论利拉鲁肽降低肥胖T2DM患者FGF21、PTP1B水平,可能与改善糖脂代谢及IR相关.

Objective To investigate the effect of Liraglutide on human serum fibroblast growth factor 21(FGF21)and protein-tyrosine-phosphataseIB(PTPIB)levels in obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 80 hospitalized obese T2DM patients with unsatisfactory glucose control were enrolled in this study from the Endocrinology Department of our hospital.All the participants were treated with metformin alone or in combination with sulfonylureas.They were randomly divided into two groups:T2DM group(Con group,n=40)and Liraglutide treatment group(LI group,n=40).The LI group started the treatment with Liraglutide on the basis of the original oral hypoglycemic agents and the T2DM group was given treatments by adjusting the dosage of the original hypoglycemic agents.All the participants were followed up for 16 weeks.Metabolic parameters FGF21 and PTP1B were recorded and analyzed before and after treatment in the two groups.Results After follow up for 16 weeks,HOMA-IR(C-P),serum FGF21 and PTP1B levels were all decreased as compared with baseline(P<0.05).The reduction was more significant in LI group than in Con group(P<0.05).Conclusion Liraglutide treatment could significantly reduce FGF21 and PTP1B levels,which may be related to the improvement of glycolipid metabolism and insulin resistance.